One-Shot cancer drug tested before surgery to shrink tumors
NCT ID NCT07349303
Summary
This study is testing if giving a single dose of an immunotherapy drug called pembrolizumab before surgery can help shrink or eliminate thick melanoma tumors. It will involve about 30 adults with stage IIb/c melanoma who are already scheduled for surgery. Patients will receive either the real drug or a placebo, and researchers will examine the tumor after removal to see if the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, 41345, Sweden
Conditions
Explore the condition pages connected to this study.